Quick Summary
Additional Context
Specialty pharmaceutical company PharmaTher Holdings is collaborating with Craft Health Pte. Ltd., a Singapore-based pharmaceutical technology company, to test whether Craft Health’s CraftMake 3D printing platform can produce personalized peptide doses. PharmaTher Holdings announced the partnership on July 29, 2026, two days after launching its Personaliz3D Peptides division.
The work will focus on six peptides: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, that the FDA’s Pharmacy Compounding Advisory Committee (PCAC) recently recommended for inclusion on the Section 503A Bulks List, the roster of substances compounding pharmacies are permitted to use. If the PCAC’s recommendation is adopted, it would open a regulated path for pharmacies to compound these peptides, and PharmaTher wan